Sublingual Epinephrine Tablets for Reliable Anaphylaxis Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering epinephrine during anaphylaxis, such as intramuscular injections, are ineffective due to the potential for insufficient absorption when blood pressure drops, and traditional oral delivery methods are not feasible for individuals experiencing anaphylaxis.
Innovation Solution
Development of sublingual epinephrine tablets containing citric acid, which create an epinephrine reservoir in the sublingual mucosa, allowing for rapid absorption and sustained plasma levels by bypassing hepatic first-pass metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intramuscular epinephrine injection is used, then treatment can be administered during anaphylaxis, but absorption is insufficient when blood pressure drops rapidly
Solution Approach 1:
The invention extracts epinephrine from the intramuscular injection route and delivers it directly to the sublingual mucosa, bypassing the vascular bed dependency. This extraction of the drug from the muscle tissue route eliminates the problem of poor absorption under low blood pressure conditions, as the sublingual route provides direct access to systemic circulation independent of muscular blood flow.
Solution Approach 2:
The sublingual mucosa serves as an intermediary tissue that facilitates epinephrine delivery to the systemic circulation. By using the sublingual mucosa as a mediator, the invention creates a reliable absorption pathway that does not depend on the patient's blood pressure status, resolving the contradiction between absorption reliability and effectiveness under hypotensive conditions.
2Ease of operation
If traditional oral delivery methods (swallowing pills) are used, then epinephrine can be delivered systemically, but the method is not feasible when airways are constricted or patient cannot swallow
Solution Approach 1:
Instead of swallowing the tablet down through the constricted airway and digestive tract, the invention inverts the approach by placing the tablet under the tongue where it dissolves directly into the sublingual mucosa. This inversion of the traditional oral route bypasses the problematic upper airway and esophageal passage, making delivery feasible during anaphylaxis while maintaining simplicity.
3Speed
If intramuscular injection is used, then epinephrine can be delivered, but it relies on a small window of opportunity to leave the vascular bed and be taken up by circulation
Solution Approach 1:
The invention prepares the epinephrine for immediate absorption by formulating it as a rapidly dissolving sublingual tablet. The tablet is designed to disintegrate quickly upon contact with saliva, creating a reservoir of epinephrine in the sublingual mucosa before systemic absorption begins. This preliminary preparation ensures rapid and consistent uptake without relying on a narrow window of vascular availability.
Solution Approach 2:
The invention changes the physical and chemical parameters of epinephrine delivery by using a sublingual formulation with specific pH and solubility characteristics. The citric acid component creates an optimal environment for epinephrine dissolution and absorption, transforming the delivery parameters to achieve both rapid onset and consistent reliability independent of blood pressure fluctuations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sublingual tablets provide faster onset of action and sustained plasma epinephrine levels, effectively treating anaphylaxis even in cases of low blood pressure, with bioequivalence or superiority to intramuscular injections.
Implementation Method 1
the citric acid aids in creating an epinephrine reservoir in the sublingual mucosa, which affords a longer duration of active absorption
Implementation Method 2
the citric acid aids in creating an epinephrine reservoir in the sublingual mucosa, which affords a longer duration of active absorption
Implementation Method 3
bypassing hepatic first-pass metabolism
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets.